Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

Published

on

<!– Name:DistributionId Value:8830816 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:1091dded-bf30-4615-a435-f645c2538b74 –>

New York, USA, May 04, 2023 (GLOBE NEWSWIRE) — Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

The increasing prevalence of diabetes patients, rise in screening for pain among diabetics, increase in the geriatric population, and launch of newly approved drugs is likely to fuel the growth of the diabetic neuropathic pain market size during the forecast period (2023–2032).

DelveInsight’s Diabetic Neuropathic Pain Market Insights report includes a comprehensive understanding of current treatment practices, diabetic neuropathic pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Diabetic Neuropathic Pain Market Report

  • As per DelveInsight analysis, the diabetic neuropathic pain market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • DelveInsight’s analysis shows that diabetic neuropathic pain cases show an increasing trend in the forecasted period in the 7MM. 
  • Leading diabetic neuropathic pain companies such as AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others are developing novel diabetic neuropathic pain drugs that can be available in the diabetic neuropathic pain market in the coming years.
  • Some of the key therapies for diabetic neuropathic pain treatment include MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others.
  • Several diabetic neuropathic pain therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major diabetic neuropathic pain market share @ Diabetic Neuropathic Pain Market Report

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain is a well-known diabetes consequence and the leading cause of all neuropathic pain. Diabetic neuropathic pain affects almost one-third of all diabetic patients. It is defined as the presence of signs and symptoms of nerve dysfunction in diabetic individuals after all other explanations have been ruled out. Prolonged high blood sugar levels can harm nerves throughout the body, but diabetic neuropathic pain most impact the legs and feet.

Diabetic neuropathic pain is characterized by tingling, burning, sharp, shooting, lancinating feelings, and electric shocks. It is usually classified as moderate to severe, and it is often worse at night, causing sleep disruption. The discomfort might be persistent and accompanied by cutaneous allodynia, which can significantly impact the patient’s quality of life, limiting their capacity to do everyday tasks and negatively impacting their mood. Pain may also be a cause of withdrawal from recreational and social activities, and it may be linked to depression.

Diabetic Neuropathic Pain Epidemiology Segmentation

The diabetic neuropathic pain epidemiology section provides insights into the historical and current diabetic neuropathic pain patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The diabetic neuropathic pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Diabetic Neuropathic Pain Prevalent Cases
  • Diabetic Neuropathic Pain Diagnosed and Treatable Cases
  • Diabetic Neuropathic Pain Gender-specific Cases  
  • Diabetic Neuropathic Pain Type-specific Cases  

Download the report to understand which factors are driving diabetic neuropathic pain epidemiology trends @ Diabetic Neuropathic Pain Epidemiological Insights

Diabetic Neuropathic Pain Treatment Market 

Current diabetic neuropathic pain treatment has two key goals: to target the underlying pathophysiological processes to avoid nerve fiber loss and reduce the unpleasant symptoms of PDN to normalize physical and psychological functioning. Tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or -aminobutyric acid (GABA) analogs (gabapentin or pregabalin) are commonly recommended as first-line medications, followed by opioids and topical therapies. Diabetic neuropathic pain is typically treated with TCAs, SNRIs, and GABA analogs. 

In September 2004, the SNRI duloxetine (Cymbalta, Eli Lilly) was licensed as the first medicine to treat the neuropathic pain associated with diabetic neuropathic pain. Duloxetine inhibits neuronal serotonin and norepinephrine reuptake. Although the specific mechanism of action of the drug’s central pain-inhibitory effect is unknown, it is thought to be connected to the potentiation of serotonergic and noradrenergic activity in the CNS. Blocking norepinephrine reuptake, in particular, has been shown to help with neuropathic pain.

Since the 1960s, traditional anticonvulsants have been utilized to treat neuropathy. However, in 2004, the FDA approved newer anticonvulsants, such as pregabalin, to treat DPN’s neuropathic pain. Because of its effectiveness in lowering pain and pain-related sleep disturbance, AAN guidelines recommend pregabalin as the first-line therapy for diabetic neuropathic pain treatment. Japan’s PMDA approved Mirogabalin for diabetic neuropathic pain treatment in 2019. Daiichi Sankyo is undertaking clinical research for Mirogabalin in the United States, with a planned launch within the study period. 

To know more about diabetic neuropathic pain treatment, visit @ Diabetic Neuropathic Pain Treatment Drugs 

Key Diabetic Neuropathic Pain Therapies and Companies

  • MEDI 7352: AstraZeneca
  • CNTX6016: Centrexion Therapeutics
  • NYX2925: Aptinyx
  • CBD/PEA: Pure Green Pharmaceuticals Inc.
  • LY3857210: Eli Lilly and Company
  • Ricolinostat: Regenacy Pharmaceuticals LLC
  • Engensis: Helixmith Co., Ltd.
  • VX-548: Vertex Pharmaceuticals Incorporated
  • E2007: Eisai Inc.
  • DA-9801: NeuroBo Pharmaceuticals Inc./Dong-A ST Co., Ltd.
  • DS-5565: Daiichi Sankyo, Inc.
  • Capsaicin Dermal Patch: NeurogesX
  • LY3526318: Eli Lilly and Company
  • LX9211: Lexicon Pharmaceuticals

Learn more about the FDA-approved drugs for diabetic neuropathic pain @ Drugs for Diabetic Neuropathic Pain Treatment 

Diabetic Neuropathic Pain Market Dynamics

The diabetic neuropathic pain market is expected to change in the coming years. One of the primary aspects recognized to influence the growth of the neuropathic pain market is the discovery of new medications for the treatment of neuropathic and chronic pains. Companies are focused on clinical studies to find therapies to treat diabetic neuropathic pain effectively. For example, Eli Lilly produced duloxetine (LY248686) for diabetic peripheral neuropathic pain (DPNP), while Daichi developed mirogabalin for DPNP. Another factor driving the expansion of the diabetic peripheral neuropathic pain market is the development of point-of-care diagnostics to identify and evaluate diabetic peripheral neuropathic pain. DPNCheck by NeuroMetrix, for example, is a rapid, accurate, and quantitative nerve conduction test used to examine nerves to detect, stage, and monitor neuropathy objectively. 

Moreover, the diabetic neuropathic pain pipeline is highly robust; many possible therapies are being studied for diabetic neuropathic pain treatment, and it is safe to assume that the therapeutic space will substantially impact the diabetic neuropathic pain market throughout the forecast period. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate will likely boost the growth of the diabetic neuropathic pain market in the 7MM.

However, certain factors may affect the growth of the diabetic neuropathic pain market. The diabetic neuropathic pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the diabetic neuropathic pain market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Diabetic Neuropathic Pain Companies AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others
Key Diabetic Neuropathic Pain Therapies MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others

Scope of the Diabetic Neuropathic Pain Market Report

  • Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and emerging therapies
  • Diabetic Neuropathic Pain Market Dynamics: Attribute Analysis of Emerging Diabetic Neuropathic Pain Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Diabetic Neuropathic Pain Market Access and Reimbursement

Discover more about diabetic neuropathic pain drugs in development @ Diabetic Neuropathic Pain Clinical Trials

Table of Contents

1. Diabetic Neuropathic Pain Market Key Insights
2. Diabetic Neuropathic Pain Market Report Introduction
3. Diabetic Neuropathic Pain Market Overview at a Glance
4. Diabetic Neuropathic Pain Market Executive Summary
5. Disease Background and Overview
6. Diabetic Neuropathic Pain Treatment and Management
7. Diabetic Neuropathic Pain Epidemiology and Patient Population
8. Patient Journey
9. Diabetic Neuropathic Pain Marketed Drugs
10. Diabetic Neuropathic Pain Emerging Drugs
11. Seven Major Diabetic Neuropathic Pain Market Analysis
12. Diabetic Neuropathic Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Diabetic Neuropathic Pain Pipeline

Diabetic Neuropathic Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Diabetic Neuropathic Pain companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.

Diabetic Neuropathy Market

Diabetic Neuropathy Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Diabetic Neuropathy Pipeline

Diabetic Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Diabetic Peripheral Neuropathy Pipeline

Diabetic Peripheral Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic peripheral neuropathy companies, including CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Helixmith, Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., among others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.

Type 1 Diabetes Market

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Diabetic Neuropathic Pain Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Stamus Networks Participates in NATO CCDCOE Locked Shields Exercise

Published

on

stamus-networks-participates-in-nato-ccdcoe-locked-shields-exercise

Leading network-based threat detection and response company part of international contingent lending personnel and technology to support world’s largest live-fire cyber defense exercise
TALLINN, Estonia, April 24, 2024 /PRNewswire/ — Stamus Networks, a global provider of high-performance network-based threat detection and response (NDR) systems, today announced its participation in Exercise Locked Shields, the largest and most complex international live-fire cyber defense exercise in the world. The annual event, which takes place this week, is organized by the NATO Cooperative Cyber Defence Centre of Excellence (CCDCOE) and aims to provide a multinational platform for enhancing partners’ cyber resilience and cooperation capabilities in a high-paced, crisis-like environment.

The exercise pits Red Teams (attackers) against Blue Teams (defenders), utilizing realistic scenarios, cutting-edge technologies, complex networks and diverse attack methods. Teams of civil and military experts must cooperate to defend critical infrastructure systems from cyberattacks.
“This exercise is a demonstration of the power of international cooperation, transcending borders, and uniting a diverse community of experts from the public and private sectors and academia,” said LtC Urmet Tomp, exercise director at NATO CCDCOE. “We are grateful for the dedication and expertise of our allies and all our partners, which are crucial in building a resilient global cyber defense.”
Since 2016, the Stamus Networks team has partnered with CCDCOE in exercises, including Locked Shields and Crossed Swords, contributing expert personnel and putting its Stamus Security Platform (SSP), the company’s flagship network-based threat detection and response system, to the test.
“True cyber resilience must be accomplished through collaboration, and there’s no better example of that on the international level than Exercise Locked Shields,” said Stamus Networks’ CEO Ken Gramley. “The lessons learned and key takeaways from the live-fire exercises that we’ve participated in over the years have been instrumental in helping organizations around the world build up defenses against today’s sophisticated cyber threats. We look forward to collaborating with experts again at this year’s exercise, not only to strengthen our own solutions, but to help defenders elevate their status as cyber heroes around the world.”
To learn more about the NATO CCDCOE and Exercise Locked Shields, visit the website: https://ccdcoe.org/exercises/locked-shields/.
About Stamus Networks: Stamus Networks believes in a world where defenders are heroes, and a future where those they protect remain safe. As organizations face threats from well-funded adversaries, we relentlessly pursue solutions that make the defender’s job easier and more impactful. The global leader in Suricata-based network security solutions, Stamus Networks helps enterprise security teams know more, respond sooner and mitigate their risk with insights gathered from cloud and on-premise network activity. Our Stamus Security Platform combines the best of intrusion detection (IDS), network security monitoring (NSM), and network detection and response (NDR) systems into a single solution that exposes serious and imminent threats to critical assets and empowers rapid response. For more information visit: stamus-networks.com.
Logo – https://mma.prnewswire.com/media/1781381/4666296/stamus_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/stamus-networks-participates-in-nato-ccdcoe-locked-shields-exercise-302125761.html

Continue Reading

Artificial Intelligence

Appdome MOBILEBot™ Defense Empowers Mobile Brands to Equalize Web Application Firewall Performance and Stop Bots Attacks Better

Published

on

appdome-mobilebot™-defense-empowers-mobile-brands-to-equalize-web-application-firewall-performance-and-stop-bots-attacks-better

New adaptive defense model allows network security teams to adjust detection and defense rules to get the most out of existing web application firewalls.
REDWOOD CITY, Calif., April 24, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, today announced three new enhancements to its MOBILEBot™ Defense solution to empower mobile brands to get more value and control from their existing web application firewall (WAF) infrastructures by adjusting the evaluation, detection, and defense policy to suit each WAF product and installation.

Cybercriminals have shifted their focus to mobile bot attacks, including weaponizing mobile apps, modified mobile apps, malware controlled mobile apps, fake mobile apps, as well as the common bot tactics like bot farms and scripts to perform brute force account takeovers, DDoS attacks and API abuse. WAF vendors have responded by providing customers with anti-bot SDKs. However, anti-bot SDKs impose too much work and too many limits on mobile app developers with too heavy a performance penalty on mobile apps in production. In addition, using these anti-bot SDKs also require costly changes to WAF infrastructures. Appdome MOBILEBot Defense provides the only way to avoid these complex challenges, making it easy for customers to deliver mobile anti-bot defense on top of any installed WAF.
The Appdome MOBILEBot Defense solution is fully portable across all new and old, on-premise and cloud WAFs. The new enhancements to MOBILEBot Defense provide adaptive evaluation, detection and defense rules that can ease and balance the compute burden on existing WAFs and infrastructures, enabling mobile brands to proactively identify and thwart bot attacks, all while reducing the strain on traditional WAFs, including those WAFs reaching their end-of-service horizons. The new Appdome enhancements allow enterprises, network security teams and mobile brands to extend the useful life of WAFs and deliver more ROI from their existing WAF investments.
“Mobile brands need to stop bot attacks, but they also need to get the most out of their WAF infrastructures and avoid costly or unplanned WAF upgrades,” said Tom Tovar, CEO and co-creator of Appdome. “Any mobile brand will likely have multiple WAFs, each with different performance characteristics. Our goal is to allow the brand to tailor the bot defense profile to meet the performance characteristics of each WAF.”
The new innovations in Appdome MOBILEBot Defense include:
Appdome DEVICETrust™: DEVICETrust is an innovative way to set the evaluation mode for connection requests and screen bot traffic and attacks. With it, mobile brands have the power to set the trust level for each threat vector and, depending on the trust setting, determine where, when and how bot detection and defense is performed. This allows for customizable trust models based on the class and type of WAF used in the bot defense infrastructure. With the new trust model mobile brands can select and prioritize the security checks that are most important to their mobile app security project goals with the click of a button.
Three modes of DEVICETrust are available with Appdome MOBILEBot Defense:
Adaptive Trust – uses the Appdome Bot Defense Framework™ intelligence to dynamically adjust the evaluation model based on the responsiveness of each WAF connected to MOBILEBot defense. Runtime-Trust – allows connection requests to proceed while threat assessment and checks are in process.Zero-Trust – holds connection requests until threat assessment and checks are complete.Appdome Bot Source and BotID:  Bot Source and BotID give mobile brands the ability to achieve continuous risk assessments by adding any data, such as business logic, to specific users and sessions in a mobile app, giving the WAF more granular rules and automated enforcement at the point of the attack, including on connection, at login, transaction, password reset, or other key application workflows.
Appdome Client Rate Limiting: Client rate limiting leverages the compute and processing power of the mobile device used in the attack, performing rate-limiting enforcement within the mobile app. Configurable limits on how frequently a user can perform an action, such as attempting to log in, within a defined timeframe. This approach is better than only relying solely on server-side rate limiting which can be susceptible to brute force and DDoS attacks.
“We’re working hard to ensure that our customers get the most out of their WAF infrastructure,” said Chris Roeckl, Appdome chief product officer. “WAFs are high performance, very capable, platforms. The antibot SDKs provided by WAF vendors are not. We’re trying to bridge the gap and give mobile brands something they can use to stop bots quickly, easily and efficiently.” 
About Appdome MOBILEBot Defense Appdome MOBILEBot Defense is the industry’s only comprehensive and fully portable anti-bot defense solution built-from-the-ground-up for mobile apps. It offers mobile brands multi-layered bot detection, intelligence, and defense all in one solution, easily protecting the mobile channel from 300+ attack vectors including fake apps, weaponized apps, malware-controlled apps, bot attacks, credential stuffing, DDoS and account takeovers (ATOs). It requires no SDK, no coding, and no added servers to deploy, and is fully compatible with all coding languages and frameworks used in mobile app development. Appdome MOBILEBot Defense is also the only product to work seamlessly with any WAF used in a mobile brand’s network. With Appdome, mobile brands are more efficiently and effectively protected from bot-driven malicious attacks, fraud, IP theft, performance drains and compliance issues at lower cost and complexity than legacy approaches.  For more information about Appdome MOBILEBot Defense, see our Knowledge Articles at  https://www.appdome.com/how-to/mobile-bot-detection/mobile-bot-defense/mobilebot-detection/.
About Appdome The Appdome mission is to protect every mobile app in the world and the people who use mobile apps in their lives and at work. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control, and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
Logo – https://mma.prnewswire.com/media/772169/AppDome_Logo_9_27_23.jpg

View original content:https://www.prnewswire.co.uk/news-releases/appdome-mobilebot-defense-empowers-mobile-brands-to-equalize-web-application-firewall-performance-and-stop-bots-attacks-better-302125390.html

Continue Reading

Artificial Intelligence

“Sopra Steria” is positioned as a Leader in the 2024 SPARK MatrixTM for Cloud-Native Application Development Services by Quadrant Knowledge Solutions

Published

on

“sopra-steria”-is-positioned-as-a-leader-in-the-2024-spark-matrixtm-for-cloud-native-application-development-services-by-quadrant-knowledge-solutions

The Quadrant Knowledge Solutions SPARK Matrix™ provides competitive analysis & ranking of the Cloud-Native Application Development Services (CNADS) vendors.  Sopra Steria, with its comprehensive technology for Cloud-Native Application Development Services, has received strong ratings across the parameters of technology excellence and customer impact.PARIS, April 24, 2024 /PRNewswire/ — Sopra Steria and Quadrant Knowledge Solutions announced today that Sopra Steria has been named as a leader in the Q1 2024 SPARK MatrixTM analysis of the global CNADS market.

 
 
The Quadrant Knowledge Solutions’ SPARK Matrix™: Cloud-Native Application Development Services, includes a detailed analysis of global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK Matrix™. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.
According to Sitaparna Roy, Analyst at Quadrant Knowledge Solutions, “Sopra Steria through its Modern Apps Development Services helps organizations to convert their ideas into Minimum Viable Product (MVP) and monitor all the development stages to production with unparalleled speed, efficiency, and productivity. It facilitates this by offering Enterprise Architect Services, Low- code/ No-code services and Cloud-Native Application development Services in its Modern Apps Development Services portfolio. […] It supports innovation through adoption of the latest technologies and tools for generating new ideas for products, services, and tools. Sopra Steria’s unique ‘BizDevSecOps’ approach for end-to-end digital transformation supports effective communication and collaboration between businesses and team operations throughout the software development life cycle.”
“Sopra Steria is proud to be recognized once again as a leader in Cloud-Native Application Development Services by Quadrant Knowledge Solutions. Our commitment to innovation, customer-centricity, and excellence in service delivery has enabled us to maintain this position for the third consecutive year. We believe that our comprehensive approach to modern application development, supported by our Cloud Center of Excellence and Ingine Platform, empowers organizations to achieve their digital transformation goals efficiently and effectively.”, comments Yann Gloriau, Cloud expert at Sopra Steria.
Click here to know more.
Logo – https://mma.prnewswire.com/media/1861938/4668457/Sopra_Steria_Logo.jpg
CONTACT: Aurélien Flaugnatti, [email protected]
 

View original content:https://www.prnewswire.co.uk/news-releases/sopra-steria-is-positioned-as-a-leader-in-the-2024-spark-matrixtm-for-cloud-native-application-development-services-by-quadrant-knowledge-solutions-302126053.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending